Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenazine methosulfate (PMS) is a polycyclic aromatic redox mediator and electron carrier primarily utilized as a research reagent in biochemical assays, such as tetrazolium-based cell viability tests (e.g., MTT, XTT). Beyond its role in electron transfer, PMS has been identified as a pharmacological inhibitor of Serine Racemase (SRR), the enzyme responsible for the synthesis of D-serine from L-serine. In the context of oncology research, particularly glioblastoma (GBM), PMS is used to modulate the tumor microenvironment by reducing D-serine levels. This inhibition disrupts the interaction between GBM cells and host endothelial cells, specifically by preventing the D-serine-mediated activation of endothelial N-methyl-D-aspartate receptors (NMDARs), thereby suppressing tumor cell migration, stemness, and aggressive progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenazine methosulfate.